Reno offers 4,050 yen share in tender for Yomeishu Seizo

Reno offers 4,050 yen share in tender for Yomeishu Seizo

Yomeishu Seizo to Participate in Taiyo Kosan’s Tender Offer for Hisamitsu Pharmaceutical Shares

Yomeishu Seizo Co., Ltd. has announced its decision to tender 101,000 shares of Hisamitsu Pharmaceutical Co., Inc. in Taiyo Kosan Co., Ltd.’s ongoing tender offer, valued at approximately 6,082 yen per share. The transaction, totaling around 614 million yen, is expected to generate an extraordinary gain of 413 million yen for Yomeishu Seizo’s fiscal year ending March 2026.

The tender offer, initiated by Taiyo Kosan, is currently open for submissions until February 19, 2026, with settlement scheduled to begin on February 27, 2026. Yomeishu Seizo’s board of directors determined that the offer’s terms, including the purchase price, were reasonable and aligned with enhancing corporate value. The decision follows a supportive opinion from Hisamitsu Pharmaceutical’s board regarding the transaction’s fairness.

By tendering all 101,000 shares, Yomeishu Seizo will no longer hold equity in Hisamitsu Pharmaceutical post-transaction. The company emphasized that this move does not alter its existing earnings guidance for the fiscal year ending March 2026.

The tender offer reflects broader strategic considerations, as Taiyo Kosan seeks to consolidate its stake in Hisamitsu Pharmaceutical. For Yomeishu Seizo, the transaction represents a non-recurring income opportunity, with the proceeds likely to be allocated toward general corporate purposes.

Investors are advised to monitor the tender offer’s progress, as its completion remains subject to regulatory approvals and shareholder responses. Further updates are expected in the coming weeks.

[Japan IR (Yomeishu Seizo Co., Ltd. - ir/2540-20260210-01_wp_tender_offer)]: Japan IR (Yomeishu Seizo Co., Ltd. - ir/2540-20260210-01_wp_tender_offer).